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Abstract
Introduction: A large number of antiepileptic drugs (AEDs) are available today, but they may not be satisfactory regarding 
clinical efﬁ  cacy, tolerance, toxicity or pharmacokinetic properties. The purpose of this review is to focus upon the rationale 
behind the chemical modiﬁ  cations of several recently marketed AEDs or drugs in development and to categorize them 
according to the main purposes for the improvements: better efﬁ  cacy or tolerability accompanied by improved pharmacokinetic 
properties.
Material and Method: AEDs that have been chemically modiﬁ  ed to new derivatives during the last years are reviewed 
based on recent publications and PubMed-searches.
Results and Discussion: Improvement in pharmacokinetic parameters may affect both tolerability and efﬁ  cacy. Modiﬁ  cations 
to improve tolerability include various valproate analogues, divided into aliphatic amides, cyclic derivatives or amino acid 
conjugates. Furthermore, there are the carbamazepine analogues oxcarbazepine and eslicarbazepine, the felbamate analogues 
ﬂ  uorofelbamate and carisbamate (RWJ 33369), and the lamotrigine analogue JZP-4. The levetiracetam analogues brivarace-
tam and seletracetam and the derivatives of gabapentin, pregabalin and XP13512, have improved selectivity compared to 
their parent compounds. Other new drugs have new mechanisms of action related to GABA and glutamate receptors; the 
glutamate antagonists like topiramate (talampanel and NS-1209), and GABAA receptor agonists, benzodiazepine or 
progesterone analogues (ELB-139 and ganaxolone).
Conclusion: Further challenges for development of new AEDs include investigations of target molecules affected by 
pathophysiological processes and detailed structure-activity relationships with focus on stereoselectivity. These potential 
drugs may become of importance in future drug therapy in epilepsy and other CNS disorders.
Keywords: antiepileptic drugs, chemical modiﬁ  cation, efﬁ  cacy, monitoring, pharmacokinetics, pharmacodynamics, 
tolerability
Introduction
A variety of antiepileptic drugs (AEDs) are available today, but still there is a need for new drugs, since 
the existing ones are not satisfactory regarding clinical efﬁ  cacy, tolerance, toxicity or pharmacokinetic 
properties. A new generation of the existing AEDs is in development, undergoing preclinical and 
clinical trials. These compounds have to be more potent, safer, and possess favorable pharmacokinetics 
to become a successful second-generation of AEDs (Bialer, 2006).
It is important to emphasize that AEDs consist of a heterogenous group of drugs with various 
chemical properties, such as lipophilicity, ionization, and chirality. They have different chemical struc-
tures, and they may affect different target proteins (receptors, enzymes, transporters or voltage-gated 
ion channels). The seizure types are different in their origin, and patients suffering from epilepsy con-
sist of a heterogenous group, phenotypically and genotypically different.
Both established and new AEDs are in clinical use or undergoing clinical trials in several psychiat-
ric and neurological disorders other than epilepsy. These include migraine, neuropathic pain, bipolar 
disorder, mania, schizophrenia, anxiety, tremor, and still other conditions are under investigation (for 
review, see Rogawski and Löscher, 2004a; Spina and Perugi, 2004; Stefan and Feuerstein, 2007; 22
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Johannessen Landmark, 2007a). The action of 
AEDs at the molecular level is incompletely 
understood, and most AEDs probably have more 
than one mechanism of action, each of which may 
contribute to the therapeutic efﬁ  cacy to a variable 
extent depending on the actual condition 
(Perucca, 2004; Johannessen Landmark, 2007a). 
It is therefore difﬁ  cult to divide the drugs into 
speciﬁ  c categories regarding their mechanisms of 
action and clinical efﬁ  cacy.
The purpose of the present review is to focus 
upon the rationale behind the chemical modiﬁ  ca-
tions of several recently marketed AEDs or drugs 
in development and to categorize them according 
to the main purposes for the improvements; namely 
better efﬁ  cacy or tolerability. These modiﬁ  cations 
are often also accompanied by improved pharma-
cokinetic properties.
Material and Methods
This review is based upon recent publications 
and PubMed searches on AEDs. The marketed 
AEDs included are carbamazepine, felbamate 
and ﬂ  uorofelbamate, gabapentin, lamotrigine, 
levetiracetam, oxcarbazepine, pregabalin, topi-
ramate, and valproate. AEDs in development 
included brivaracetam, eslicarbazepine (BIA 
2-093), ELB139, JZP-4, NS1209, carisbamate   
(RWJ 33369), talampanel, XP13512, and val-
proic acid derivatives (propylisopropyl acetamide 
(PID), 2,2,3,3- tetramethylcyclopropanecarbon-
ylurea (TMCU), N-methyl-2,2,3,3-tetramethyl-
cyclopropylamide (MTMCD), valnoctamide and 
valrocemide). The older AED phenytoin with its 
derivative fosphenytoin was not included, since 
this derivative has existed for almost ten years 
and the clinical use is limited to injections used 
in the treatment of status epilepticus.
Search terms used were the AEDs mentioned 
above, anticonvulsant, epilepsy, mechanism of 
action, efﬁ  cacy, tolerability, and pharmacokinetic 
properties, and combinations of these terms.
Relevant peer-reviewed articles in recognized, 
creditable international journals in English, from 
the earliest relevant data, 1983–2007, were 
included in the review. Primary sources were pre-
ferred, but review articles of speciﬁ  c importance 
were also included. Abstracts, unpublished or non-
English material, and papers of limited relevance 
or out-of-date results or choice of methods were 
excluded.
Strategies for Modiﬁ  cations
and Monitoring of AEDs
Most AEDs have several mechanisms of action, and 
focus has been on designing new AEDs with speciﬁ  c 
mechanisms of action, or more selective effects on 
known target molecules for pharmacodynamic 
effects (Fig. 1). The major improvements of the new 
derivatives are listed in Table 1. Chemical modiﬁ  ca-
tions resulting in a better pharmacokinetic proﬁ  le 
have been emphasized for improving AEDs, result-
ing in better tolerability and efﬁ  cacy (Fig. 2).
Basic pharmacokinetic parameters are the fac-
tors in the body that affects the drug from the time 
it is taken, including absorption, distribution, 
metabolism and excretion (Fig. 2). A drug is 
absorbed to the systemic circulation, where it may 
be bound to plasma proteins or distributed through-
out body tissues (fat or ﬂ  uid). From the systemic 
circulation the free fraction (which may be neutral 
or ionized) of the drug is transported to its site of 
action to exert its pharmacodynamic effect. The 
drug is undergoing elimination via biotransforma-
tion through metabolic pathways and elimination 
(often through liver, kidneys and faeces). Other 
parameters derived from these basic processes are 
e.g. bioavailability and half-life, which affect the 
efﬁ  cacy of the drug, to which extent it reaches the 
site of action and how long it remains in the sys-
temic circulation. A prolonged half-life of a drug 
or changed distribution in various body tissues may 
affect the efﬁ  cacy of the drug. Therapeutic drug 
monitoring (TDM) is a useful tool also in the treat-
ment of patients using older as well as newer AEDs 
(Johannessen and Tomson, 2002; 2006) Monitor-
ing of AEDs gives the opportunity to observe 
pharmacokinetic and pharmacodynamic interac-
tions, to avoid side effects and toxic levels and 
active metabolites in the blood (Fig. 2).
In the following, each of the parent drugs will 
be brieﬂ  y described, regarding pharmacological 
characteristics, including mechanism of action and 
clinical use and limitations. Chemical characteris-
tics and modiﬁ  cations will then be described and 
discussed.
Improved Tolerability of New AEDs
The tolerability of AEDs has often been improved 
by modiﬁ  cations of pharmacokinetic properties to 
reduce potential toxic metabolic pathways or 
teratogenic effects, as for valproate, carbamazepine, 
and felbamate (Fig. 1).23
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Figure 1. Main proposed mechanisms of action of newer antiepileptic drugs (AEDs) in the inhibitory GABAergic and the excitatory glutama-
tergic synapse. The black spots are reuptake proteins for GABA and glutamate (two distinct, selective proteins). The grey receptor sites are 
metabotropic receptors, GABAB for GABA and mGluR, for glutamate.
Abbreviations: SV2A: synaptic vesicle protein 2A, the speciﬁ  c binding site for levetiracetam; VGCC and VGSC are voltage-gated calcium- 
and sodium channels, respectively. (Modiﬁ  ed from Johannessen Landmark, 2007).
Table 1. A new generation of existing AEDs, their parent compound and improvements.
New compound Parent AED Improvement Characteristics
Brivaracetam
Seletracetam
Levetiracetam Efﬁ  cacy More potent binding to SV2A
Oxcarbazepine
Eslicarbazepine
Carbamazepine Tolerability Improved pharmacokinetic 
properties
Fluorofelbamate Felbamate Tolerability Non-toxic metabolite
JZP-4 Lamotrigine Efﬁ  cacy Improved pharmacokinetic 
properties and efﬁ  cacy
Pregabalin Gabapentin Efﬁ  cacy Equally potency to gabapentin
Valrocemide, Valnoctamide,Propylisopropyl 
acetamide (PID), N-methyl-2,2,3,3-
tetramethylcyclopropylamide 
(MTMCD),NPS-1776, Tetramethyl-
cyclopropancarbonylurea (TMCU)
Valproate Tolerability Less toxic metabolites, less 
teratogenic potential
Postsynaptic neuron
Ca2+
Na+
Cl-
Glutamate
Excitatory synapse Inhibitory synapse
GABA A
AMPA
NMDA
GABAB
mGluR
GABA
Ca2+
Valrocemide
Valnoctamide
PID, MTMCD?
Ganaxolone
ELB-139
Talampanel, NS-1209
Fluorofelbamate
Carisbamate (RWJ-333369)
Eslicarbazepine
Oxcarbazepine
Brivaracetam
Seletracetam
Intra-
cellular
signalling
pathways
Excitability
SV2a
JZP-4
Na+
Action potential
VGCC
VGSC
Pregabalin
XP-1351224
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Modiﬁ  cations of valproic acid
Parent drug: Valproic acid/valproate
Proposed mechanisms of action
Valproic acid or valproate, its corresponding base 
which most often is used in drug formulation, is 
a broad spectrum AED. It has been investigated 
through the past four decades with demonstrated 
effects in a variety of elecrophysiological, neu-
rochemical, seizure and animal models, and 
several mechanisms of action have been pro-
posed. Attention has been drawn to effects on 
enhancement of GABAergic neurotransmission, 
where valproate affects several enzymes related 
to GABA synthesis and degradation (Löscher, 
2002ab; Johannessen and Johannessen, 2003; 
Johannessen Landmark, 2007b). The effect of 
valproate on voltage-gated sodium channels, in 
addition to potassium and calcium channels, is 
no longer regarded as an important clinically 
relevant mechanism of action (Löscher, 2002ab; 
Johannessen et al. 2001; Johannessen and Johan-
nessen, 2003).
In addition, valproate is involved in modulation 
of intracellular signalling pathways. Effects on 
these intracellular proteins are regarded as 
important for the understanding of the patho-
physiology of bipolar disorder as well as the 
efﬁ  cacy of valproate in bipolar disorder (Rogawski 
and Löscher, 2004ab; Anmann and Grünze, 2005; 
Johannessen Landmark, 2007ab). Intracellular 
targets include modulation of inositol metabolism, 
kinases as ERK and MARCK, glycogen synthase-
3, protein kinase C, and early inducible genes 
(Göttlicher et al. 2001; Phiel et al. 2001; Löscher, 
2002ab; Johannessen and Johannessen, 2003; 
Harwood and Agam, 2003; Ju and Greenberg, 
2003; Brunello and Tascedda, 2003; Anmann and 
Grünze, 2005). Altered expression of a number of 
different genes expressed following valproate 
treatment in mice, indicates that valproate regu-
lates a large number of different functional path-
ways in the brain (Chetcuti et al. 2005).
Clinical use
Valproate is widely used in a number of neuro-
logical and psychiatric disorders today. It is 
extensively used in epilepsy and is effective in 
all seizure types, in addition to neuropathic pain, 
migraine, and bipolar disorder (Rogawski and 
Löshcer, 2004a; Spina and Perugi, 2004; 
Johannessen Landmark, 2007a; Anmann et al. 
ABSORPTION
(unchanged / modified)
BOUND DRUG
(blood / tissue)
UNBOUND DRUG
(blood)
EXCRETION
(unchanged / modified)
BIOTRANSFORMATION
(liver, other tissues)
EFFECT
Pharmacokinetic
modifications for
improved tolerability
TDM:
Monitoring of blood
levels of AEDs and
possible metabolites
for optimalized therapy
to minimize side
effects, interactions and
toxicity
Pharmacodynamic
modifications for
improved efficacy
Possible
formation of toxic
metabolites
Figure 2. Pharmacokinetic paramaters. A drug is absorbed to the systemic circulation, where the drug may be bound to plasma proteins or 
distributed throughout body tissues (fat or ﬂ  uid). It is only the free fraction of the drug in plasma that can exert an effect. From the systemic 
circulation the drug is transported to its site of action to exert its pharmacodynamic effect. The drug is undergoing elimination via biotrans-
formation through metabolic pathways and elimination (often through liver, kidneys and faeces). The block arrows point to modiﬁ  cations in 
efﬁ  cacy by pharmacodynamic (mechanism of action) factors, and tolerability by modiﬁ  cations of pharmacokinetic parameters.25
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2007). Valproate is under investigations for 
further extensive clinical use, as in schizophrenia, 
neuroprotection and cancer (Dou et al. 2003; Eyal 
et al. 2005; Ichikawa et al. 2005; Yeow et al. 
2006). Since valproate has several proposed 
mechanisms of action, it is regarded as a broad-
spectrum drug with a wide therapeutic 
potential.
A fatale adverse effect of valproate is hepato-
toxicity, its toxic metabolite being 4-ene valproate 
(Bailie, 1992). Children less than 2 years old 
receiving Valproate in polytherapy and suffering 
from metabolic genetic disorders appear to be at 
highest risk for developing fatal hepatic dysfunc-
tion (1/600) (Bryant and Dreifuss, 1996). Another 
restriction in the clinical use of valproate is the risk 
of teratogenicity. The incidence of congenital mal-
formations in the offspring of mothers treated with 
valproate during pregnancy is 3 to 4 times higher 
than in offspring not exposed to valproate (Kaneko 
et al. 1999; Tomson et al. 2004; Perucca, 2005; 
Aldenkamp et al. 2006).
Valproic acid analogues
A number of analogues have been investigated, 
and several of them have been designed as stable 
amide derivatives of valproic acid with no acidic 
function or minimal conversion to the acid (Bialer 
and Yagen, 2007). Three strategies have been 
implemented in this attempt, the development of 
aliphatic amide analogues, cyclic derivatives, and 
amino acid conjugates, (Bialer, 2006; Bialer and 
Yagen, 2007).
Some of the main derivatives will be brieﬂ  y 
presented including valrocemide (valproyl glyc-
inamide), the tetramethylcyclopropyl analogue 
(TMCU) and isovaleramide (NPS 1776) 
(Isoherränen, 2001ab; Bialer et al. 2006; Sobol 
et al. 2006) (Fig. 3). The valproic acid amide 
derivatives, valnoctamide, di-isopropylacetamide, 
and N-methyl-2,2,3,3- tetramethyl-cyclopropyl-
amide (MTMCD) show more potent antiallodynic 
effects than valproic acid and exert minimal motor 
and sedative side effects at analgesic doses in a 
rat model of neuropathic pain and may conse-
quently, become new drugs for the treatment of 
neuropathic pain (Winkler et al. 2005ab). Inves-
tigations of the clinically relevant mechanisms of 
these second-generation substances are still ongo-
ing. Valrocemide is undergoing phase II in clinical 
development (Bialer et al. 2006).
Chemical characteristics
and modiﬁ  cations of valproic acid
and its derivatives
Valproic acid (di-n-propyl acetic acid) or valproate, 
its corresponding base, and its simple structure of 
a short, branched fatty acid differs to a great extent 
from the substituted heterocyclic ring structures 
characterizing other older AEDs. Some of its 
derivatives are illustrated for comparison with the 
simple structure of the parent drug (Fig. 3).
Aliphatic amide analogues and amino acid
conjugates
The amide derivatives are more potent than valproic 
acid and their corresponding acids, and a series of 
structure-pharmacokinetic-pharmacodynamic rela-
tionships have been studied (Winkler, 2005 ab; 
Sobol et al. 2006; Bialer, 2006).
In the simple structure of PID, the molecule is 
an acetamide, but the propyl isopropyl skeleton is 
present, resulting in one chiral center. It is the 
corresponding amide of valproic acid. In valroce-
mide, a glycinamide is attached to the carboxylic 
acid end of the molecule. In valnoctamide the 
carboxylic acid in vaplroic acid is replaced here 
by an amide like in PID, and one methyl group is 
reorganized to achieve two chiral centra. Racemic 
valnoctamide and the stereoisomers (2R,3S)- and 
(2S,3S) valnoctamide (with the best brain penetra-
tion) were demonstrated to be effective anticon-
vulsants in animal models of partial seizures and 
were more potent than valproic acid (Isoherrränen 
et al. 2003). It seems reasonable that only one pair 
of the racemate is pharmacologically active, since 
biological complexing usually is stereoselective.
Cyclic derivatives
N-methyl-2,2,3,3- tetramethylcyclopropylamide 
MTMCD (MTMCD) is a cyclopropylamide with 
four methyl groups, and several other cyclic 
derivatives have been developed, as TMCU 
(Bialer, 2006; Sobol et al. 2006). TMCU is similar 
to MTMCD but has an amide attached. These 
cyclic analogues possess two quanternary carbons 
in the β-position and cannot be biotransformed 
into the minor metabolites of valproic acid, 4-ene-
VPA and 2,4-diene-VPA with a terminal double 
bond, which is presumed to be the source of 
hepatotoxicity (Konig et al. 1999; White et al. 
2002; Sobol et al. 2005).26
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Modiﬁ  cations of carbamazepine
Parent drug: Carbamazepine
Proposed mechanism of action
The main action of carbamazepine is mediated 
through inhibition of voltage-activated sodium 
channels and consequently, inhibition of action 
potentials and excitatory neurotransmission. 
High frequency, repetitive neuronal firing is 
therefore limited (Kuo, 1998; Kuo et al. 2004). 
The inhibitory potency is strongly use-dependent 
and accumulates with prolonged activation 
(Rogawski and Löscher, 2004b). This is a classic 
mechanism of action for AEDs that is also shared 
by e.g. the older drug phenytoin, and several 
other AEDs as one of more mechanisms of action. 
In addition, as for valproate modulation of intra-
cellular signalling pathways has been shown to 
be important for understanding of the patho-
physiological background for bipolar disorder 
(Rogawski and Löscher, 2004a; Anmann and 
Grünze, 2005).
Oxcarbazepine
Oxcarbazepine differs from carbamazepine as the 
drug inhibits several types of voltage-gated calcium 
channels (Ahmad et al. 2005). Also for oxcarbaze-
pine, modulation of intracellular signalling pathways 
is important for the pathophysiological background 
for bipolar disorder (Rogawski and Löscher, 2004a; 
Anmann and Grünze, 2005). Oxcarbazepine is a 
O
OH
O
OH
Valproic acid           4-ene-VPA (heptatoxic metabolite) 
O
HN
NH2
O
O
NH2
*
O
NH2
*
*
Valrocemide          Propyl isopropyl acetamide (PID)             Valnoctamide 
N
O
H
MTMCD 
Figure 3. Valproic acid, its toxic metabolite and several of the valproic acid analogues.27
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non-toxic derivative of carbamazepine with a 
reduced drug interaction potential (Bialer et al. 2004; 
Schmidt and Elger, 2004).
Clinical use of carbamazepine and oxcarbazepine
Oxcarbazepine has been available in Europe for 
many years but only recently in the US. Carbam-
azepine and oxcarbazepine are widely used in 
several neurological and psychiatric disorders. 
Carbamazepine is regarded as a ﬁ  rst-line drug in 
epilepsy, and it is also frequently used in neuro-
pathic pain and bipolar disorder (Rogawski and 
Löscher, 2004a; Spina and Perugi, 2004; 
Johannessen Landmark, 2007a; Bialer et al. 2007; 
Anmann et al. 2007). Both drugs are broad-
spectrum drugs, based on their mechanisms of 
action and wide clinical use.
The goal for developing the derivatives of car-
bamazepine has been to avoid the potentially toxic 
epoxide-metabolite skin rash and less susceptibil-
ity to pharmacokinetic interactions, as it does not 
undergo inducible cytochrome CYP3A4-mediated 
oxidative metabolism in the liver (Bialer, 2006).
Eslicarbazepine (BIA 2-093)
The carbamazepine analogue eslicarbazepine 
acetate, BIA 2-093, (S9-(-)-10-acetoxy-10,11-
dihydro-5H-dibenz/b,f/azepine-5-carboxamide 
was designed for improved efﬁ  cacy and safety 
(Bialer et al. 2007). BIA 2-093 is a derivative of 
carbamazepine and oxcarbamazepine, and is a 
prodrug for the main active metabolite (S)-
licarbazepine (Bialer et al. 2007). The compound 
is currently undergoing clinical phase III trials in 
epilepsy and phase II trials in bipolar disorder 
(Bialer et al. 2007).
Chemical characteristics and modiﬁ  cations 
of carbamazepine and its derivatives
Carbamazepine is a dibenzoazepine, a carbamate, 
its main metabolite being the 10,11-epoxide. This 
unstable epoxide is not toxic, in contrast to other 
epoxides that are formed after enzymatic degradation 
in the liver (Fig. 4). In the structure of its derivative 
oxcarbazepine, there is addition of a ketone group 
on the N-containing cyclic structure. Oxcarbazepine 
is a prodrug for the main active metabolite, mono-
hydroxy derivative (MHD), 10-hydroxy-10,11-
dihydro carbazepine, that can be measured in the 
blood for therapeutic drug monitoring purposes 
(Johannessen and Tomson, 2006). BIA 2-093 is a 
dibenzazepine derivative of carbamazepine and 
oxcarbamazepine, and is a prodrug for the main 
active metabolite (S)-licarbazepine, which is one of 
the enantiomers of MHD (Fig. 4).
Modiﬁ  cations of felbamate
Parent drug: Felbamate
Proposed mechanisms of action
Felbamate is regarded as a broad-spectrum AED with 
several proposed mechanisms of action, including 
antagonism at the glutamatergic NMDA receptor at 
the NR2 subunit, in clinically relevant concentrations 
(Kuo et al. 2004). Other mechanisms of action 
include inhibition of voltage-gated sodium and cal-
cium channels (Rogawski and Löscher, 2004b).
Clinical use
After serious adverse events including aplastic 
anemia and liver failure caused by production of 
a reactive metabolite of felbamate in a limited 
number of the patient population, the use of the 
drug was thoroughly considered. The clinical use 
of felbamate is now limited and is only used in 
some forms of refractory epilepsy and Lennox 
Gastaut syndrome in children (Perucca, 2004).
Fluorofelbamate
A non-toxic analogue, ﬂ  uorofelbamate, 2-phenyl-
2-ﬂ  uoro-1,3-propanediol dicarbamate, was devel-
oped due to the serious adverse effects of felbamate. 
Its mechanisms of action cannot be completely 
explained by either interactions at glutamate recep-
tor sites or sodium channels (Wallis et al. 2000). 
It protects against ischemia and hypoxia in vitro 
and in vivo (Wallis et al. 2000). Fluorofelbamate 
is undergoing preclinical trials, and has shown to 
be effective in a rat model of status epilepticus 
(Mazarati et al. 2002; Bialer et al. 2007). Pre-
clinical ﬁ  ndings suggest that ﬂ  uorofelbamate is not 
metabolized to the known reactive metabolite of 
felbamate, where possibly the upper amide group 
is cleaved off the molecule to give felbamate 
2-phenylpropanal (ATPAL) (Parker et al. 2005). 
The ﬂ  uor atom will protect the amide groups by 
its inductive effect, as the size of the ion radius of 
ﬂ  uor compared to hydrogen is similar.28
Landmark and Johannessen
Perspectives in Medicinal Chemistry 2008:2
Carisbamate (RWJ-333369)
Another derivative of felbamate is carisbamate, 
(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol. 
Carisbamate (RWJ-333369) is undergoing phase II 
and III clinical trials and seems to be well tolerated 
(Bialer, 2006; Bialer et al. 2007). The compound 
has been tested in several preclinical models and 
has a favorable proﬁ  le in epilepsy models, such as 
corneal kindling, hippocampus kindling, a genetic 
absence epilepsy rat model (GAERS) and chemically 
induced seizures (Bialer et al. 2007).
Chemical characteristics and modiﬁ  cations 
of felbamate and its derivatives
Felbamate is a symmetrical molecule with a ben-
zene ring structure attached to a central carbon 
atom with a diether binding to two amide groups 
(Fig. 5). In ﬂ  uorofelbamate one ﬂ  uor atom is 
attached to the central carbon atom to prevent the 
formation of the reactive toxic metabolite of fel-
bamamate, ATPAL (Bialer, 2006) (Fig. 5). In 
carisbamate a chloride atom is attached to the 
aromatic ring, and an amide containing side chain 
N
NH2 O
N
NH2 O
O
Carbamazepine-10,11-epoxide Carbamazepine
N
NH2 O
O
N
NH2 O
HO
N
NH2 O
O
O
*
Oxcarbazepine
10-hydroxy-10,11-dihydro carbazepine (MHD)
Eslicarbazepine acetate (BIA 2-093)
Figure 4. Metabolism of carbamazepine and its derivative oxcarbazepine and eslicarbazepine.29
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has been included, resulting in a chiral centrer 
(Fig. 5).
Modiﬁ  cations of lamotrigine
Parent drug: Lamotrigine
Proposed mechanisms of action
The principal mechanism of action of lamotrigine 
appears to involve inhibition of voltage-activated 
sodium channels, resulting in increased inhibition 
of action potential firing activity by a use- 
dependent mechanism (Xie et al. 1995; Kuo, 
1998). Lamotrigine also inhibits high-voltage-
activated calcium channels that are located presyn-
aptically, including the N- and P-type, and 
consequently, inhibits neurotransmitter release, 
such as glutamate (Xie and Hagan, 1998). Another 
novel mechanism of action is that lamotrigine 
selectively decreases action potential ﬁ  ring by an 
increase in the dendritic hyperpolarization-acti-
vated cation current (Ih), since the dendrites have 
different electrical properties from the soma in 
pyramidal cells (Poolos et al. 2002). This target 
would be of importance in epileptogenesis (Poolos 
et al. 2002).
Clinical use
Lamotrigine is extensively used in epilepsy, neu-
ropathic pain, and bipolar disorder, based on its 
inhibitory effect on excitatory neurotransmission 
(Rogawski and Löscher, 2004ab; Spina and Perugi, 
2004; Eisenberg et al. 2005; Nierneberg et al. 
2006). In addition, lamotrigine may be beneﬁ  cial 
in the treatment of other disorders, such as migraine 
or schizophrenia (Rogawski and Löscher, 2004a; 
Lampl et al. 2005; Muzina et al. 2005; Premkumar 
and Pick, 2006; Johannessen Landmark, 2007a; 
Anmann et al. 2007).
JZP-4
JZP-4, 3-(2,5-trichloro-phenyl)-pyrazine-
2,6-diamine, is a derivative of lamotrigine. It is a 
novel potent sodium and calcium channel inhibitor, 
which displays broad-spectrum anticonvulsant 
activity (Bialer et al. 2007). The substance has 
demonstrated a favorable proﬁ  le in toxicology and 
pharmacokinetic studies so far (Bialer et al. 2007).
Chemical characteristics
and modiﬁ  cations of lamotrigine
and its derivative
Lamotrigine is a 1,2,4-triazine, with two chloride atoms 
attached (Fig. 6). In JZP-4, one nitrogen atom has been 
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Figure 5. Felbamate and its derivatives, ﬂ  uorofelbamate and carisbamate (RWJ 33369). The cleavage of felbamate to the toxic metabolite 
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removed from the cyclic structure, and another 
chloride is attached to the aromatic ring (Fig. 6). The 
two drugs are different in structure since cyclic struc-
tures with two nitrogen atoms are commonly occurring 
in biological molecules, while three nitrogens are not 
common. Both molecules are neutral in physiological 
pH. The modiﬁ  cations in JZP-4 may affect the meta-
bolic route of elimination for lamotrigine.
Comments
In this section, chemical modiﬁ  cations of AEDs, 
developed to reduce toxic effects, the risks of spe-
ciﬁ  c adverse effects and interaction potential have 
been described. The new derivatives have improved 
tolerability and pharmacokinetic properties. The 
main AEDs used today in epilepsy and other disor-
ders as bipolar disorder and neuropathic pain are 
valproate, carbamazepine and lamotrigine. These 
drugs have several new effective and safe deriva-
tives that hopefully will be clinically useful within 
the coming years.
Improved Efﬁ  cacy of New AEDs
One way to improve efﬁ  cacy of AEDs is by design-
ing a better pharmacodynamic proﬁ  les with more 
speciﬁ  c mechanisms of action based on new patho-
physiological ﬁ  ndings. New AEDs in development 
will hopefully result in better chemical and phar-
macological characteristics than the existing sub-
stances. The proposed mechanisms of action of 
these drugs are illustrated in the synapses by the 
main inhibitory neurotransmitter GABA and the 
main excitatory neurotransmitter glutamate with 
their main targets for pharmacological action 
(Fig. 1). The main pharmacodynamic mechanisms 
responsible for the clinical efﬁ  cacy of AEDs include 
increased GABAergic or decreased glutamatergic 
neurotransmission, inhibition of voltage-gated ion 
channels or modiﬁ  cations of intracellular signalling 
pathways (Rogawski and Löscher, 2004b; 
Johannessen Landmark, 2007b). A common result 
of pharmacological intervention with these drugs 
is a decrease in neuronal excitability. The main 
modiﬁ  cations of AEDs and their main achievements 
are listed in Table 1. Most AEDs bind to target 
macromolecules where the neurotransmitters 
GABA or glutamate bind, such as receptors and 
transporters, or to voltage-gated ion channels. 
Structurally, some of the AEDs may have structural 
similarities with these amino acid neurotransmitters 
(Fig. 7), such as gabapentin. Most AEDs have 
several target molecules in common with the endog-
enous neurotransmitters (receptors, enzymes, 
reuptake proteins). In addition, pregabalin and 
gabapentin are structurally related to GABA.
Modiﬁ  cations of levetiracetam
Parent drug: Levetiracetam
Proposed mechanisms of action
Levetiracetam is a unique broad-spectrum AED 
that did not show any effect in the commonly used 
epilepsy models, but it was effective in a genetic 
absence epilepsy model (GAERS) (Bialer et al. 
2004, Stratton et al. 2003). A novel binding site 
for levetiracetam has been identiﬁ  ed as the syn-
aptic vesicle protein 2A (SV2A) in the presynap-
tic neuron (Lynch et al. 2004). It is still unclear 
how levetiracetam and SV2A interact, but it has 
been proposed that it is essential for exocytosis of 
neurotransmitter from the presynaptic neuron into 
the synaptic cleft and may prevent exocytosis of 
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Figure 6. Lamotrigine and its derivative JZP-4.31
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glutamate, since there is a correlation between 
binding afﬁ  nity and potency in suppressing tonic 
seizures in audiogenic sensitive mice (Lynch et al. 
2004). In addition, for other AEDs like gabapentin 
and pregabalin that target voltage-activated 
sodium and calcium channels (including α2δ), 
inhibition of glutamate release is likely to be a 
critical downstream action for seizure protection 
(Rogawski and Löscher, 2004a; Rogawski, 2006). 
Levetiracetam may also inﬂ  uence GABAergic 
activity by increasing chloride currents and con-
sequently enhancement of inhibitory GABAergic 
neurotransmission, and glycin could also be 
affected (Poulain et al. 2002; Rigo et al. 2002). 
Inhibition of glycin release could indirectly reduce 
the activity of the NMDA receptor of glutamate, 
since this receptor is dependant on the binding of 
both glutamate and glycin to open the ion channel. 
Recently, enhancement of release of inhibitory 
neurotransmitters has also been proposed (Stefan 
and Feuerstein, 2007). It seems more likely, how-
ever, that exocytosis is inhibited rather than 
enhanced when levetiracetam possibly interacts 
with the docking process of exocytosis of neu-
rotransmitter from the presynaptic neuron.
Clinical use
Levetiracetam is used in epilepsy and neuropathic 
pain and is under investigation for further clinical 
use, as in essential tremor (Rogawski and Löscher, 
2004a; Handforth and Martin, 2004; Bushara et al. 
2005; Johannessen Landmark, 2007a). It is 
extensively used in several seizure types in many 
patients with refractory epilepsy (Bialer et al. 2007; 
Stefan and Feuerstein, 2007; Johannessen Landmark 
et al. 2007).
Brivaracetam and seletracetam
Two promising novel drug derivatives of leveti-
racetam are in developement, brivaracetam 
(ucb 34714) and seletracetam (ucb 44212). They 
optimize the unique mechanism of action and 
may further improve medical management of 
epilepsy (Klitgaard, 2005; Von Rosenstiel et al. 
2007; Bennett et al. 2007). Brivaracetam could 
possibly have a broader therapeutic spectrum 
than its parent drug since it also inhibits voltage 
gated sodium channels (Rogawski, 2006). These 
derivatives have been tested in phase I studies 
(Bialer et al. 2007). Comparable studies of the 
two drugs are, however, lacking, regarding 
mechanisms of action and efﬁ  cacy in preclinical 
models.
Chemical characteristics
and modiﬁ  cations of levetiracetam 
and its derivatives
Levetiracetam is a 5-oxopyrolidine with a lactam 
ring structure with one chiral centre, and the 
S-enantiomer is present (Fig. 8). Seletracetam 
and brivaracetam are derivatives of levetiracetam 
that are substituted at the 4-position in the 
2-pyrrolidinone ring (Fig. 8). The chemical dif-
ference in the two new compounds is the addition 
of a propyl group in brivaracetam. In seletrace-
tam, a vinyl group including two ﬂ  uor atoms is 
added in the same position as a steric hinder to 
avoid chemical interactions. All three molecules 
are neutral in physiological pH. The two deriva-
tives have one additional chiral centre, giving 
two stereoisomers each. Stereoselectivity in the 
binding of these molecules seems likely to occur. 
These modifications result in a potentiated 
binding to the SV2A protein, up to 10-fold 
compared to levetiracetam in several models for 
epilepsy, like cornea kindling and the GAERS 
absence seizure model (Crowder et al. 1999, 
Lynch et al. 2004, Bennett et al. 2007, Von 
Rosenstiel et al. 2007).
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Figure 7. The main inhibitory and excitatory amino acid neurotransmitters in the brain, GABA and glutamate, respectively.32
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Modiﬁ  cations of gabapentin
Parent drug: Gabapentin
Proposed mechanisms of action
Gabapentin was synthesized as a GABAergic 
substance and is structurally related to GABA, but 
does not interact with GABA receptors or its uptake 
or degradation processes (Sills, 2006). Gabapentin 
and pregabalin are ligands of α2δ ￿ (1 and 2) voltage-
activated calcium channel subunits that are over-
expressed in sensory neurons after nerve injury 
(Marais et al. 2001; Bian et al. 2006). Inhibition 
of voltage-gated calcium channels in the presyn-
aptic neuron will inhibit glutamate release at 
excitatory synapses and thereby a decrease in 
excitatory neurotransmission (Rogawski and 
Löscher, 2004a).
Pregabalin
A structurally related compound to gabapentin is 
pregabalin, (S)- 3-aminomethyl-5-methylhexanoic 
acid. Pregabalin has the same binding-afﬁ  nity as 
gabapentin to the α2δ (1 and 2) subunits, which 
strongly implicates that these subunits are important 
for the pharmacological effect (Marais et al. 2001; 
Bian et al. 2006). The subunits are major binding 
proteins for pregabalin in neocortex, hippocampus, 
amygdala, and spinal cord, as demonstrated in 
genetically modified mice (Bian et al. 2006). It 
remains to be determined, however, whether an 
interaction with high-voltage-activated calcium 
channels is sufﬁ  cient to account for the broad-spec-
trum activity of gabapentin and pregabalin (Sills, 
2006).
Clinical use of gabapentin and pregabalin
Gabapentin and pregabalin have recognized 
efﬁ  cacy in the treatment of both epilepsy and neu-
ropathic pain, and to some extent in migraine, and 
they are both marketed in many countries (Landy 
et al. 2004; Sills, 2006). The inhibition of voltage-
gated calcium channels is supposed to be involved 
in pain relief (Marais et al. 2001; Rogawski and 
Löshcer, 2004a, Sills, 2006; Bian et al. 2006). 
Gabapentin has also demonstrated efﬁ  cacy in essen-
tial tremor, which is associated with a deﬁ  ciency 
in GABAergic function (Kralic et al. 2005; Jankovic 
and Noebels, 2005; Rodrigues et al. 2005).
XP13512
A new derivative is in development as a prodrug 
of gabapentin, XP13512, [( + /−)-1-([(alpha-isobu
tanoyloxyethoxy)carbonyl] aminomethyl)-1-
cyclohexane acetic acid], avoiding capacity-limited 
absorption from the intestine following oral admin-
istration (Cundy et al. 2004; Bialer, 2006). It is 
going through phase II in clinical trials (Bialer, 
2006). Its potential clinical use will possibly be 
primarily epilepsy and neuropathic pain.
Chemical characteristics
and modiﬁ  cations of gabapentin
and its derivatives
The structures of gabapentin and pregabalin are 
derived from GABA, but they are one atom longer, 
with six instead of ﬁ  ve carbon or nitrogen atoms in 
a row. Both drugs are inactive at GABA receptors 
(Taylor et al. 2006) (Fig. 9). Unlike GABA both 
drugs have bulky aliphatic chemical substitutions at 
the 3-position of GABA, which changes their 
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pharmacological properties significantly in 
comparison to GABA (Taylor et al. 2006). In gaba-
pentin, there is an amino acid-like structure with a 
carboxylic acid ending and one amino group ending, 
attached to a cyclohexane (Fig. 9). In pregabalin, 
there is a central chiral atom in the 4-position, and 
the amino acid-like structure is kept. The cyclic 
hexane structure has been replaced with an aliphatic 
side chain. These aliphatic amines are positively 
charged at physiological pH. The gabapentin deriv-
ative XP13512 has got an addition of a diesther group 
to the amino ending of the molecule (Fig. 9).
Compounds related to topiramate
Parent drug: Topiramate
Proposed mechanisms of action
Topiramate is a pharmacologically rich neuroactive 
drug that has been demonstrated to possess many 
molecular activities, such as inhibition of voltage-
gated sodium channels, modulation of voltage-
gated potassium and calcium channels, modulation 
of GABAA and glutamate receptors, and carbonic 
anhydrase inhibition (Bialer et al. 2004; White, 
2005). Among its complex actions, topiramate is 
a selective antagonist at the glutamatergic kainate 
receptor, a potential and important target regarding 
minimizing the potential toxicity caused by 
prolonged glutamatergic activation by NMDA 
receptors (Kaminski et al. 2004; Muir, 2006). It is 
rather remarkable that the unusual structure of 
topiramate may affect these distinct targets includ-
ing receptors, ion channels and enzymes.
Clinical use
Topiramate is used in epilepsy, migraine and tremor 
(Silberstein et al. 2004; White, 2005; Bialer et al. 
2007). Topiramate may have a potential for clinical 
use in treatment-resistant schizophrenia, even 
though the outcome was moderate in one clinical 
study (Tiihonen et al. 2005). Furthermore, the drug 
has been tested in other neurological and 
psychiatric conditions, such as anxiety, bipolar 
disorder, and neuropathic pain (Van Ameringen 
et al. 2004; Bartolini et al. 2005; McIntyre et al. 
2005; Johannessen Landmark, 2007a).
The following compounds are not structurally 
related to topiramate, but are compounds with a 
similar mechanism of action compared to some of 
the actions mediated by topiramate, e.g. antagonists 
to glutamatergic and GABAergic receptors. Efforts 
have been focused on improving the selectivity of 
potential AEDs to these receptors.
Talampanel
It has been difﬁ  cult to develop antagonists to iono-
tropic glutamate receptors, both due to the high 
endogenous extracellular glutamate concentration 
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Figure 9. Gabapentin and its derivatives pregabalin and XP13512.34
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and the possible side effects on cognition and 
memory. Talampanel is a selective non-competitive 
antagonist at the AMPA receptor (Rogawski, 2006; 
Solyom et al. 2002). Talampanel has been sug-
gested to be active in neuroprotection as well as in 
epilepsy (Bialer, 2006). Two putative noncompeti-
tive antagonist sites are known. These binding sites 
are linked to the cation channel of the AMPA recep-
tor (Bialer et al. 2007). Clinical trials of talampanel 
are ongoing in phase II (Bialer et al. 2007).
NS1209
NS1209 is a selective, competitive AMPA receptor 
antagonist (Rogawski, 2006; Solyom et al. 2002). 
AMPA receptors are key mediators for seizure 
spread. Calcium permeability of AMPA receptors 
lacking the GluR2 subunit in the amygdala and 
hippocampus has been studied, and they could play 
a role in synaptic plasticity, epileptogenesis and 
excitotoxicity (Gryder et al. 2005). These receptors 
are promising targets for further investigations. 
There is a recognized glutamate binding site on the 
AMPA receptor subunit, where competitive antag-
onists like NS1209 bind.
Chemical characteristics
and modiﬁ  cations of topiramate
and related compounds
The following structures are not very similar 
chemically but bind to a common target protein, 
the AMPA receptor. Topiramate is a tetrahydropy-
rane with one sulphonamide attached. Two acetal 
groups with two methyl groups each are attached 
to the molecule to protect the substituents (Fig. 10). 
Talampanel is a diazepine derivative, the 3-
acetylated, 3-4-dihydro analogue of GYKI 52466, 
which is the prototype of the 2,3-benzodiazepine 
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class of AMPA receptor antagonists (Donevan and 
Rogawski, 1993). NS1209 is an indole derivative 
included in a big heterocyclic structure with several 
attached groups, including one sulphonamide 
group (Fig. 10). They are large heterogenous mol-
ecules and differ in functional groups, which 
indicate that the whole molecule is not involved in 
the binding for pharmacological effect.
Benzodiazepines, neurosteroids
and their derivatives: GABAA agonists
Parent drugs: Benzodiazepines
Proposed mechanisms of action
The benzodiazepines bind to the benzodiazepine 
receptor within the benzodiazepine-GABAA recep-
tor complex. Agonists at the GABAA receptor 
enhance the inhibitory GABAergic neurotransmis-
sion throughout the CNS. The various GABAA 
receptor subtypes are different in their speciﬁ  c 
regional and cellular localization, they conse-
quently serve distinct neuronal circuits and func-
tions. A deficit in the α3-subunit in GABAA 
receptors was linked to dopaminergic hyperfunc-
tion, which is considered to be a contributing fac-
tor to the development of schizophrenia, and 
agonists at these receptors would be of importance 
(Yee et al. 2005).
Clinical use
Benzodiazepines are used worldwide as anxiolyt-
ics, sedatives and anticonvulsant drugs. The 
potential for development of tolerance, depen-
dence and abuse, is, however, a limitation in their 
clinical use (Löscher and Schmidt, 2006). The new 
derivatives may have a clinical potential in anxiety 
and epilepsy.
ELB139
Various selective partial benzodiazepine receptor 
agonists are being developed, including ELB139, 
[1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-
imidazol-2-on], a positive allosteric modulator of 
α3-containing GABAA receptors (Langen et al. 
2005). In a recent study, ELB139 showed func-
tional subtype speciﬁ  city to several GABAA recep-
tor subtypes, and partial agonism at various 
subtypes, differently from diazepam (Rabe et al. 
2007). Its main clinical use seems to be anxiety, 
although it may have a potential in epilepsy 
(Rogawski, 2006).
Ganaxolone
Ganaxolone (3-α-hydroxy-3-β-methyl-5-α-
pregnan-20-on) is the 3-β-methylated synthetic 
analogue of allopregnanolone (Fig. 11). It is a 
neuroactive progesterone-analogue that acts as a 
positive modulator of GABAA receptors, since 
there is a speciﬁ  c binding site for these pregnano-
lones (Foster and Kemp, 2006). It is a member of 
a novel class of neuroactive steroids called epal-
ones, and it allosterically modulates the GABAA 
receptor complex via a unique recognition site 
(Bialer et al. 1999). Ganaxolone has demonstrated 
efﬁ  cacy in preliminary clinical trials, in infantile 
spasms in children and as monotherapy in adults 
(Kerrigan et al. 2000; Laxer et al. 2000). It is 
currently undergoing further development in 
infantile spasms, in women with catamenial epi-
lepsy, and in adults with refractory partial-onset 
seizures (Nohria and Giller, 2007). The potential 
for clinical use of ganaxolone seems to be rather 
limited based on the absence of recent publica-
tions of further investigations regarding this drug, 
possibly due to pharmacokinetic problems and 
limited absorption, and reformulation of the drug 
is ongoing (Bialer et al. 1999; Nohria and Giller, 
2007).
Chemical characteristics
and modiﬁ  cations of benzodiazepines, 
neurosteroids and their derivatives
GABAA-agonists
Chemically, ELB-139 is related to the benzodiaz-
epines, as both drugs consist of heterocyclic ring 
structures that possibly bind similarily to the 
GABAA receptor, although this new derivative is 
subtype selective.
Neurosteroids
Ganaxolone has a steroid skeleton very similar 
to progesterone, with a difference in the 
hydroxyl group instead of a keton and a double 
bond in the A-ring of the cholesterol skeleton 
(Fig. 11). It lacks, however, hormonal activity 
(Bialer et al. 1999).36
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Comments
In this section important target molecules for AEDs 
have been discussed in relation to the different 
classes of AEDs. The molecules that have been 
focused upon include voltage gated sodium and 
calcium channels, proteins associated with exocy-
tosis of neurotransmitters (SV2A), and receptor 
molecules for GABA (GABAA) and glutamate 
(AMPA receptors). Further investigations with 
potential AEDs should be accompanied by phar-
macogenetic studies to elucidate modiﬁ  cations in 
the target molecules of AEDs, which also may be 
altered in pathophysiological processes (as in 
anxiety with altered subunit expression of the 
GABAA receptors and neuropathic pain where an 
over-expression of the α2δ subunits of the voltage-
gated calcium channel is present).
Conclusions
Several AEDs of a new generation have been 
developed from the existing drugs. Develoment of 
new derivatives is important to achieve new drugs 
with improved pharmacokinetic and—dynamic 
properties, resulting in better tolerability and efﬁ  -
cacy. The AEDs consist of a group of heterogenous 
chemical structures, unrelated to each other, but 
affecting the same target proteins. Important target 
molecules, which have been focused upon include 
voltage gated sodium and calcium channels, pro-
teins associated with exocytosis of neurotransmit-
ters, and receptor molecules for GABA and 
glutamate. New drugs will hopefully affect patho-
physiological processes or altered target proteins 
more selectively than older drugs. Further effort 
should be put into more detailed structure-activity 
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relationship studies including investigations 
regarding stereoselectivity. There will be a resistant 
need for improvement of efﬁ  cacy and tolerability 
of the existing drugs, as well as newly discovered 
substances with novel mechanisms of action may 
become of importance in future drug therapy in 
epilepsy in addition to other CNS disorders.
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